This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Dec;9(12):674.

doi: 10.1038/nrcardio.2012.151. Epub 2012 Nov 13.

Dyslipidemia: Phase III trial of mipomersen in heterozygous FH

Bryony M Mearns

PMID: 23149832
DOI: 10.1038/nrcardio.2012.151

Comment

Dyslipidemia: Phase III trial of mipomersen in heterozygous FH

Bryony M Mearns. Nat Rev Cardiol. 2012 Dec.

. 2012 Dec;9(12):674.

doi: 10.1038/nrcardio.2012.151. Epub 2012 Nov 13.

Author

Bryony M Mearns

PMID: 23149832
DOI: 10.1038/nrcardio.2012.151

No abstract available

PubMed Disclaimer

Comment on

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Stein EA, et al. Circulation. 2012 Nov 6;126(19):2283-92. doi: 10.1161/CIRCULATIONAHA.112.104125. Epub 2012 Oct 11. Circulation. 2012. PMID: 23060426 Clinical Trial.

References

1. Circulation. 2012 Nov 6;126(19):2283-92 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Miscellaneous
- NCI CPTAC Assay Portal